Last updated: September 2, 2026
Secnidazole is a differentiated oral nitroimidazole marketed in the United States as Solosec by Lupin. Its commercial proposition is a single 2-gram oral dose in flavored granules for bacterial vaginosis and trichomoniasis. The product benefits from treatment convenience and limited direct branded competition, but its growth is constrained by low-cost generic metronidazole, payer restrictions, patient affordability and the absence of separately reported product revenue from Lupin.
What is secnidazole and how is it marketed?
Secnidazole is a 5-nitroimidazole antimicrobial related to metronidazole and tinidazole. In the U.S., Solosec is supplied as oral granules in a single-dose 2-gram packet. Patients sprinkle the granules over soft food and consume the full dose without chewing.
The FDA approved Solosec in September 2017 for bacterial vaginosis in adult females. The FDA later approved an expanded indication for trichomoniasis in adults. Solosec is prescription-only and is positioned around adherence rather than broad-spectrum differentiation. [1]
| Product |
Active ingredient |
U.S. dosage form |
Main U.S. indications |
Commercial owner |
| Solosec |
Secnidazole |
2-gram oral granules |
Bacterial vaginosis; trichomoniasis |
Lupin |
| Flagyl and generics |
Metronidazole |
Tablets, capsules, gel, cream, infusion |
Bacterial vaginosis; trichomoniasis and other infections |
Multiple manufacturers |
| Tindamax and generics |
Tinidazole |
Tablets |
Trichomoniasis; bacterial vaginosis and other infections |
Multiple manufacturers |
| Cleocin and generics |
Clindamycin |
Oral, vaginal and topical forms |
Bacterial vaginosis and other infections |
Multiple manufacturers |
The key commercial distinction is dosing. Secnidazole can be administered as a single oral dose, while common metronidazole regimens require multiple doses over several days. The advantage is clinically relevant where incomplete adherence is a concern, but it is difficult to sustain a large price premium against inexpensive generic alternatives.
What is the FDA regulatory status of Solosec?
Solosec has full U.S. approval under NDA 209363. The FDA label identifies secnidazole as an oral antimicrobial for adult bacterial vaginosis and adult trichomoniasis. [1]
FDA milestones
| Date |
Regulatory event |
| September 2017 |
FDA approval for bacterial vaginosis |
| 2017 onward |
U.S. commercialization under the Solosec brand |
| 2021 |
FDA approval for trichomoniasis in adults |
| Current status |
Approved prescription product marketed by Lupin |
The trichomoniasis indication expanded the addressable market, but it also placed Solosec against established generic therapies. The CDC’s sexually transmitted infection guidance continues to identify metronidazole as a standard treatment for trichomoniasis, with tinidazole as an alternative. That treatment environment limits automatic substitution toward secnidazole. [2]
For bacterial vaginosis, clinical guidelines historically have centered on metronidazole and clindamycin. Secnidazole is an alternative regimen, particularly for patients who value single-dose oral administration or have difficulty completing multi-day therapy. [3]
How large is the secnidazole market?
The global secnidazole market is difficult to measure because the active ingredient has been available for years in multiple countries through generic and branded products. The commercially relevant market differs sharply by geography.
United States
The United States is the highest-value market for Solosec because Lupin sells a branded, FDA-approved single-dose product. The U.S. opportunity includes:
- Adult bacterial vaginosis treatment.
- Adult trichomoniasis treatment.
- Patients with poor adherence to multi-day regimens.
- Patients seeking an oral alternative to vaginal products.
- Prescribers and health systems emphasizing treatment completion.
The U.S. market is commercially concentrated. Solosec has brand recognition and an approved granule formulation, but metronidazole and tinidazole generics set a low reference price.
International markets
Outside the United States, secnidazole is widely exposed to generic competition. It is sold in various countries for anaerobic infections, protozoal infections, bacterial vaginosis and sexually transmitted infections. Local formulations, regulatory approvals, physician habits and reimbursement systems determine market share.
International volume does not translate directly into Lupin revenue because product rights and manufacturing arrangements vary by country. The company’s U.S. Solosec business is therefore more important to the branded financial thesis than aggregate global secnidazole volume.
What is the financial trajectory for Solosec and Lupin?
Lupin does not separately disclose a complete, audited annual revenue series for Solosec. It reports the product within its U.S. branded portfolio, which prevents precise calculation of Solosec’s standalone revenue, gross margin and operating profit from public financial statements.
The product entered Lupin’s portfolio through the 2017 acquisition of Symbiomix Therapeutics. Lupin announced consideration of up to approximately $150 million, including upfront and contingent payments, for the company and its Solosec asset. [4]
Financial trajectory
| Period |
Financial development |
Interpretation |
| 2017 |
Lupin acquired Symbiomix and obtained Solosec |
Lupin purchased a branded U.S. women’s-health platform rather than an established large-scale franchise |
| 2017-2019 |
Commercial launch and prescriber development |
Revenue ramp depended on education, reimbursement and patient access |
| 2020-2021 |
Trichomoniasis indication expanded the label |
Addressable market increased, but generic competition remained intense |
| 2022 onward |
Product remained part of Lupin’s U.S. branded portfolio |
Growth depends on refill-free prescription volume, coverage and price realization |
| Current reporting |
No separate Solosec revenue line |
Standalone valuation requires company disclosures, prescription data or channel research |
The product’s financial profile is likely more attractive at the gross-margin level than at the volume level. A branded single-dose product can generate meaningful revenue per prescription, while manufacturing costs for oral granules are relatively modest. The main expenses are commercial promotion, payer contracting, patient support, distribution and sales-force activity.
Revenue is sensitive to three variables:
- Prescription volume.
- Net price after rebates and discounts.
- The mix between commercially insured, Medicaid and cash-paying patients.
A high list price does not necessarily indicate high net sales. Women’s-health products often face substantial payer variation, and prior authorization or non-preferred formulary status can shift prescribing toward generic metronidazole.
What drives secnidazole market growth?
Single-dose adherence advantage
The strongest commercial argument is treatment completion. Solosec avoids the need for patients to remember multiple daily doses over several days. This can help in infections where nonadherence contributes to persistent symptoms, recurrence or return visits.
The value proposition is practical rather than novel pharmacology. Secnidazole’s mechanism is familiar within the nitroimidazole class. The product’s differentiation comes from formulation, dosing and positioning.
Women’s-health specialization
Lupin can target gynecologists, primary-care physicians, sexual-health clinics and public-health providers. Bacterial vaginosis is common, and trichomoniasis remains a significant sexually transmitted infection. The product’s women’s-health focus provides a specialized commercial position compared with broad generic antimicrobial portfolios.
Expanded indication
The trichomoniasis indication increased the number of clinical situations in which physicians can prescribe Solosec. The label expansion also creates opportunities for cross-indication promotion within sexual-health practices.
Recurrence and retreatment
Bacterial vaginosis has a substantial recurrence burden. Recurrence can increase the number of treatment episodes, but it does not guarantee branded use. Clinicians commonly retreat with generic metronidazole, clindamycin or other guideline-supported regimens.
What limits secnidazole market growth?
Generic price competition
Metronidazole is inexpensive, familiar and available in oral and vaginal forms. Tinidazole and clindamycin also provide alternatives. For many payers and health systems, the incremental cost of Solosec is difficult to justify unless adherence or patient preference is a priority.
Payer access
Coverage is central to the Solosec business model. A prescription can be lost when the product is non-preferred, requires prior authorization or carries a high copay. Patient savings programs can support utilization but also reduce net price.
Limited clinical differentiation
Secnidazole is not a new antimicrobial class. Physicians familiar with metronidazole may perceive limited need to switch. The product must therefore compete on convenience, tolerability, patient preference and completion rates.
Antimicrobial stewardship
Public-health and institutional stewardship policies favor appropriate, targeted antimicrobial use and discourage unnecessary treatment. Secnidazole does not benefit from a broad “new antibiotic” premium because it belongs to an established class.
What patents protect secnidazole and Solosec?
Solosec’s principal intellectual-property value is associated with the product’s oral granule formulation, composition and use rather than with the underlying secnidazole molecule. Secnidazole itself is an old active ingredient and is not protected as a new chemical entity in the United States.
A principal U.S. patent publicly associated with Solosec is:
| Patent |
Subject matter |
Patent holder or originator association |
Publicly reported term |
| U.S. Patent No. 9,192,644 |
Secnidazole pharmaceutical composition and related product protection |
Symbiomix-originated estate; commercial rights held by Lupin |
Expiration generally reported in 2031, subject to applicable term adjustments |
The commercial estate may also include formulation, manufacturing, dosing and method-of-use rights in different jurisdictions. The scope of any generic challenge depends on which claims are listed in the FDA Orange Book, whether those claims remain enforceable and whether a challenger can establish invalidity, noninfringement or lack of liability.
Because secnidazole is an old molecule, generic manufacturers can potentially compete through different dosage forms or non-infringing formulations. The branded barrier is stronger when claims cover the specific granule composition and administration method used by Solosec.
When does secnidazole lose exclusivity?
Solosec’s regulatory and patent exclusivity should be analyzed separately.
Regulatory exclusivity
The initial 2017 approval included the regulatory protections applicable to the product and indication at that time. Those periods are finite and do not prevent all possible competition with secnidazole products approved through other regulatory pathways.
Patent exclusivity
The key commercial question is whether an ANDA applicant can enter before the expiry of the relevant formulation or method patents. If the principal listed patent expires around 2031, generic entry could occur earlier through:
- A Paragraph IV challenge.
- A settlement providing a negotiated launch date.
- A non-infringing formulation.
- A product approved for a different indication.
- A patent invalidity ruling.
The effective loss-of-exclusivity date could therefore precede the nominal patent expiration date.
Are there Paragraph IV challenges to Solosec?
A Paragraph IV challenge is the standard ANDA pathway for a generic applicant to assert that an Orange Book-listed patent is invalid, unenforceable or not infringed. A complete assessment requires current FDA Orange Book and federal court records.
The commercial implications are material even before a final judgment. A Paragraph IV filing can trigger patent litigation, potentially create a 30-month stay of FDA approval and establish a settlement negotiation framework. If the first qualifying ANDA applicant obtains 180-day exclusivity, the initial competitive environment may be limited to one generic manufacturer.
No broad multi-generic launch should be assumed solely from the age of secnidazole. The relevant barriers are the listed formulation patents, FDA approval requirements for the granule dosage form, manufacturing capability and payer contracting.
What is the generic launch risk for Solosec?
Generic launch risk is moderate over the near term and increases materially as the principal formulation patents approach expiration.
Near-term risk
Near-term erosion is more likely to come from:
- Physician substitution to existing metronidazole regimens.
- Formulary exclusions.
- Lower-cost tinidazole or clindamycin.
- International generic reference pricing.
- Reduced promotional investment.
Patent-expiry risk
After relevant formulation protection expires, multiple generic manufacturers could enter if the dosage form is commercially attractive. The likely result would be:
- Rapid net-price compression.
- Lower branded prescription volume.
- Reduced payer support.
- A shift from branded granules to lower-cost tablets or alternative formulations.
- Lower strategic value for Solosec within Lupin’s portfolio.
The market may still retain a branded niche if patients and prescribers value the single-dose product, but that niche would probably be smaller after generic entry.
How does secnidazole compare with metronidazole and tinidazole?
| Factor |
Secnidazole |
Metronidazole |
Tinidazole |
| Typical commercial position |
Branded convenience product |
Low-cost standard therapy |
Generic alternative with longer dosing options |
| Oral dosing convenience |
Single 2-gram dose for Solosec |
Often multiple doses |
Often one- or multi-day regimens |
| U.S. generic exposure |
Limited branded-product competition in the Solosec formulation |
Extensive |
Extensive |
| Price position |
Premium |
Low |
Low to moderate |
| Main differentiation |
Granules and single-dose administration |
Familiarity, availability and cost |
Dosing flexibility |
| Strategic risk |
Payer resistance and future formulation generics |
Low pricing |
Generic substitution |
Secnidazole has the clearest convenience advantage, but metronidazole has the strongest cost and familiarity advantage. The commercial winner depends on the payer, clinical setting and patient adherence profile.
What licensing deals and corporate transactions affect secnidazole?
The principal transaction was Lupin’s acquisition of Symbiomix Therapeutics in 2017. The deal transferred the Solosec commercial asset and related intellectual property to Lupin. [4]
No major subsequent licensing transaction has become central to the public Solosec investment case. Lupin’s strategy has been direct commercialization through its U.S. branded portfolio rather than reliance on a large external licensing network.
What is the competitive outlook for secnidazole?
The competitive outlook is stable but constrained.
Solosec has a defensible commercial niche based on:
- Single-dose administration.
- FDA approval for two relevant indications.
- A recognized U.S. brand.
- A formulation-oriented patent estate.
- Lupin’s established U.S. commercial infrastructure.
The limitations are equally clear:
- The active ingredient is old.
- Low-cost alternatives are entrenched.
- Standalone revenue is not publicly disclosed.
- Payer access determines prescription conversion.
- Patent protection is formulation-led and finite.
- There is no biologic exclusivity or biosimilar moat.
Biosimilar risk is not relevant because secnidazole is a small-molecule drug, not a biologic. The relevant competitive risk is generic substitution.
What is the investment and revenue exposure?
Solosec is unlikely to be a principal driver of Lupin’s consolidated financial results. Lupin’s broader portfolio includes respiratory, cardiovascular, diabetes, gastrointestinal, anti-infective and specialty products. Solosec contributes to the U.S. branded segment but is not separately reported as a major consolidated revenue line.
Its financial importance is greater at the portfolio level:
- It adds a branded U.S. product with potential pricing leverage.
- It diversifies Lupin beyond generic prescription products.
- It provides exposure to women’s health.
- It uses existing U.S. sales and distribution capabilities.
- It carries future erosion risk concentrated in one formulation estate.
The most credible financial scenario is gradual branded growth or stabilization before generic pressure, followed by sharp revenue compression if a successful ANDA launch occurs. A sudden blockbuster trajectory is less likely without stronger payer coverage, broader prescriber adoption or additional indications.
Key Takeaways
- Secnidazole is marketed in the United States as Solosec, a single-dose 2-gram oral granule product owned by Lupin.
- FDA-approved uses include bacterial vaginosis and adult trichomoniasis.
- The product’s main advantage is adherence and convenience, not a new mechanism.
- Metronidazole, tinidazole and clindamycin generics impose substantial price pressure.
- Lupin does not separately disclose a full Solosec revenue history.
- Lupin acquired Symbiomix and Solosec in 2017 in a transaction valued at up to roughly $150 million.
- Patent protection centers on the formulation and use of secnidazole rather than the old active ingredient.
- U.S. Patent No. 9,192,644 is publicly associated with Solosec and is generally reported to expire in 2031.
- Paragraph IV litigation and generic formulation development are the principal U.S. exclusivity risks.
- Biosimilar risk does not apply; generic-drug risk does.
- The likely commercial trajectory is a specialized branded niche followed by material erosion after formulation protection weakens.
FAQs
Is secnidazole more effective than metronidazole?
Secnidazole offers comparable therapeutic positioning for approved indications but is differentiated mainly by single-dose administration. It is not generally established as a universally superior antimicrobial to metronidazole.
Is Solosec available as a generic?
The active ingredient secnidazole is available generically in some countries, but U.S. competition with Solosec depends on FDA approval of a competing product and the status of formulation patents.
Does Solosec require refrigeration?
Solosec storage requirements are specified in the FDA-approved prescribing information. The product should be handled according to the current label and pharmacy dispensing instructions. [1]
Can secnidazole be used for infections beyond its FDA-approved indications?
Physicians may prescribe drugs off-label in appropriate circumstances, but Solosec’s FDA-approved U.S. indications are bacterial vaginosis in adult females and trichomoniasis in adults. [1]
What is the largest commercial threat to Solosec?
The largest threat is substitution by low-cost generic metronidazole, reinforced by payer restrictions. A successful generic launch targeting the Solosec granule formulation would create a larger and more direct threat after relevant patent protection expires.
References
-
U.S. Food and Drug Administration. (2021). Solosec (secnidazole) oral granules prescribing information. FDA.
-
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines: Trichomoniasis. CDC.
-
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1-187.
-
Lupin Limited. (2017, July 20). Lupin acquires Symbiomix Therapeutics and Solosec in the United States. Lupin Limited.
-
U.S. Patent and Trademark Office. (2013). U.S. Patent No. 9,192,644: Pharmaceutical compositions comprising secnidazole. USPTO.
